866-997-4948(US-Canada Toll Free)

Bladder Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Bladder Cancer

No. of Pages : 285 Pages

Bladder Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Bladder Cancer - Pipeline Review, H2 2014, provides an overview of the Bladder Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bladder Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Bladder Cancer - Overview 11
Pipeline Products for Bladder Cancer - Comparative Analysis 12
Bladder Cancer - Therapeutics under Development by Companies 13
Bladder Cancer - Therapeutics under Investigation by Universities/Institutes 18
Bladder Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Bladder Cancer - Products under Development by Companies 23
Bladder Cancer - Products under Investigation by Universities/Institutes 27
Bladder Cancer - Companies Involved in Therapeutics Development 28
Shionogi & Co., Ltd. 28
AstraZeneca PLC 29
Eli Lilly and Company 30
Viralytics Ltd. 31
GlaxoSmithKline plc 32
Bioniche Life Sciences, Inc. 33
Bavarian Nordic A/S 34
Biotest AG 35
Daiichi Sankyo Company, Limited 36
Merck & Co., Inc. 37
Samyang Holdings Corporation 38
Astellas Pharma Inc. 39
Eisai Co., Ltd. 40
Marina Biotech, Inc. 41
Genmab A/S 42
Celgene Corporation 43
Bayer AG 44
Advaxis, Inc. 45
Evotec AG 46
Immunomedics, Inc. 47
Alnylam Pharmaceuticals, Inc. 48
Oncogenex Pharmaceuticals, Inc. 49
Dendreon Corporation 50
Sanochemia Pharmazeutika AG 51
OncoTherapy Science, Inc. 52
Quest PharmaTech Inc. 53
Synta Pharmaceuticals Corp. 54
Med Discovery SA 55
Hutchison MediPharma Limited 56
Altor BioScience Corporation 57
Telormedix SA 58
Gene Signal International SA 59
Merrimack Pharmaceuticals, Inc. 60
Innate Therapeutics Limited 61
Stemline Therapeutics, Inc. 62
BioCancell Therapeutics, Inc. 63
AndroScience Corporation 64
Serum Institute of India Limited 65
Dompe Farmaceutici S.p.A. 66
NuCana BioMed Limited 67
Polaris Group 68
Serometrix, LLC 69
Regulon Inc. 70
SentoClone International AB 71
Optimum Therapeutics, LLC 72
Lipella Pharmaceuticals, Inc. 73
APIM Therapeutics AS 74
EntreChem, S.L. 75
Immunservice GmbH 76
Qu Biologics Inc. 77
Panacela Labs, Inc. 78
Tolero Pharmaceuticals, Inc. 79
Oncopeptides AB 80
DormaTarg, Inc. 81
AlphaMab Co., Ltd 82
Mirati Therapeutics Inc. 83
Bladder Cancer - Therapeutics Assessment 84
Assessment by Monotherapy Products 84
Assessment by Combination Products 85
Assessment by Target 86
Assessment by Mechanism of Action 90
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 99
pembrolizumab - Drug Profile 99
apatorsen - Drug Profile 101
mocetinostat - Drug Profile 103
paclitaxel-loaded polymeric micelle - Drug Profile 106
paclitaxel - Drug Profile 108
ramucirumab - Drug Profile 111
ALT-801 - Drug Profile 116
imiquimod - Drug Profile 118
BC-819 - Drug Profile 119
lapuleucel-t - Drug Profile 121
AZD-4547 - Drug Profile 123
SentoClone - Drug Profile 125
astuprotimut-R - Drug Profile 127
recMAGE-A3 + AS15 - Drug Profile 128
CV-301 - Drug Profile 130
IMMU-132 - Drug Profile 131
S-588410 - Drug Profile 132
eribulin mesylate - Drug Profile 133
indatuximab ravtansine - Drug Profile 137
CVA-21 - Drug Profile 139
afuresertib hydrochloride + trametinib dimethyl sulfoxide - Drug Profile 143
MMD-37K - Drug Profile 145
patritumab - Drug Profile 146
HuMax-TF-ADC - Drug Profile 148
PVP Hypericin - Drug Profile 149
MM-111 - Drug Profile 150
NUC-1031 - Drug Profile 152
AZD-5312 - Drug Profile 154
ASG-15ME - Drug Profile 155
AGS-15E - Drug Profile 156
GSK-2849330 - Drug Profile 157
BAY-1163877 - Drug Profile 158
MDRG-01 - Drug Profile 159
MDP-01 - Drug Profile 160
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 161
OGX-225 - Drug Profile 162
SL-601 - Drug Profile 163
TMX-202 - Drug Profile 164
BC-821 - Drug Profile 165
MDR-09521 - Drug Profile 166
SL-052 - Drug Profile 167
aganirsen - Drug Profile 169
pegargiminase - Drug Profile 171
cisplatin liposomal - Drug Profile 174
MIS-416 - Drug Profile 176
EC-7072 - Drug Profile 178
RNAi Oligonucleotide for Bladder Cancer - Drug Profile 179
Mobilan - Drug Profile 180
ASC-JM.Z1 - Drug Profile 182
ATX-101 - Drug Profile 183
LNP-dsP21-322-2'F - Drug Profile 184
TP-3654 - Drug Profile 185
Melflufen - Drug Profile 186
DT-310 - Drug Profile 188
DT-320 - Drug Profile 189
DT-330 - Drug Profile 190
Recombinant Protein for Bladder Cancer and GBM - Drug Profile 191
Monoclonal Antibodies to Inhibit N-Cadherin for Bladder and Metastatic Hormone Refractory Prostate Cancers - Drug Profile 192
ICT-2700 - Drug Profile 193
Lm-LLO-ISG15 - Drug Profile 194
HMPL-453 - Drug Profile 196
BV-2711 - Drug Profile 197
OTS-964 - Drug Profile 198
HDC-SN-38 - Drug Profile 199
Drugs to Antagonize CXCR1/2 for Bladder and Prostate Cancer - Drug Profile 201
suramin hexasodium - Drug Profile 202
SX-MTR1 - Drug Profile 204
QBECP SSI - Drug Profile 205
KN-014 - Drug Profile 206
Small Molecules to Inhibit CD147 for Immunology, Oncology, Womens Health and Musculoskeletal Disorders - Drug Profile 207
Bladder Cancer Vaccine - Drug Profile 208
Drug for Bladder Cancer - Drug Profile 209
MDNA-55 - Drug Profile 210
Drugs to Inhibit FGFR3 for Cancer - Drug Profile 211
Small Molecules to Activate Caspase 3 and Caspase 9 for Bladder and Urinary Tract Cancer - Drug Profile 212
ISANIL-02 - Drug Profile 213
Bladder Cancer - Recent Pipeline Updates 214
Bladder Cancer - Dormant Projects 267
Bladder Cancer - Discontinued Products 269
Bladder Cancer - Product Development Milestones 270
Featured News & Press Releases 270
Appendix 278
Methodology 278
Coverage 278
Secondary Research 278
Primary Research 278
Expert Panel Validation 278
Contact Us 279
Disclaimer 279

List of Tables
Number of Products under Development for Bladder Cancer, H2 2014 17
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Comparative Analysis by Unknown Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2014 33
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2014 34
Bladder Cancer - Pipeline by AstraZeneca PLC, H2 2014 35
Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2014 36
Bladder Cancer - Pipeline by Viralytics Ltd, H2 2014 37
Bladder Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 38
Bladder Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 39
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 40
Bladder Cancer - Pipeline by Biotest AG, H2 2014 41
Bladder Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 42
Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2014 43
Bladder Cancer - Pipeline by Samyang Holdings Corporation, H2 2014 44
Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2014 45
Bladder Cancer - Pipeline by Eisai Co., Ltd ., H2 2014 46
Bladder Cancer - Pipeline by Marina Biotech, Inc., H2 2014 47
Bladder Cancer - Pipeline by Genmab A/S, H2 2014 48
Bladder Cancer - Pipeline by Celgene Corporation, H2 2014 49
Bladder Cancer - Pipeline by Bayer AG, H2 2014 50
Bladder Cancer - Pipeline by Advaxis, Inc., H2 2014 51
Bladder Cancer - Pipeline by Evotec AG, H2 2014 52
Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2014 53
Bladder Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 54
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 55
Bladder Cancer - Pipeline by Dendreon Corporation, H2 2014 56
Bladder Cancer - Pipeline by Sanochemia Pharmazeutika AG, H2 2014 57
Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2014 58
Bladder Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 59
Bladder Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 60
Bladder Cancer - Pipeline by Med Discovery SA, H2 2014 61
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 62
Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2014 63
Bladder Cancer - Pipeline by Telormedix SA, H2 2014 64
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2014 65
Bladder Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 66
Bladder Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 67
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2014 68
Bladder Cancer - Pipeline by BioCancell Therapeutics, Inc., H2 2014 69
Bladder Cancer - Pipeline by AndroScience Corporation, H2 2014 70
Bladder Cancer - Pipeline by Serum Institute of India Limited, H2 2014 71
Bladder Cancer - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 72
Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2014 73
Bladder Cancer - Pipeline by Polaris Group, H2 2014 74
Bladder Cancer - Pipeline by Serometrix, LLC, H2 2014 75
Bladder Cancer - Pipeline by Regulon Inc., H2 2014 76
Bladder Cancer - Pipeline by SentoClone International AB, H2 2014 77
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2014 78
Bladder Cancer - Pipeline by Lipella Pharmaceuticals, Inc., H2 2014 79
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2014 80
Bladder Cancer - Pipeline by EntreChem, S.L., H2 2014 81
Bladder Cancer - Pipeline by Immunservice GmbH, H2 2014 82
Bladder Cancer - Pipeline by Qu Biologics Inc., H2 2014 83
Bladder Cancer - Pipeline by Panacela Labs, Inc., H2 2014 84
Bladder Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 85
Bladder Cancer - Pipeline by Oncopeptides AB, H2 2014 86
Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2014 87
Bladder Cancer - Pipeline by AlphaMab Co., Ltd, H2 2014 88
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2014 89
Assessment by Monotherapy Products, H2 2014 90
Assessment by Combination Products, H2 2014 91
Number of Products by Stage and Target, H2 2014 94
Number of Products by Stage and Mechanism of Action, H2 2014 98
Number of Products by Stage and Route of Administration, H2 2014 101
Number of Products by Stage and Molecule Type, H2 2014 104
Bladder Cancer Therapeutics - Recent Pipeline Updates, H2 2014 220
Bladder Cancer - Dormant Projects, H2 2014 273
Bladder Cancer - Dormant Projects (Contd..1), H2 2014 274
Bladder Cancer - Discontinued Products, H2 2014 275

List of Figures
Number of Products under Development for Bladder Cancer, H2 2014 17
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 19
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Products, H2 2014 27
Assessment by Monotherapy Products, H2 2014 90
Assessment by Combination Products, H2 2014 91
Number of Products by Top 10 Target, H2 2014 92
Number of Products by Stage and Top 10 Target, H2 2014 93
Number of Products by Top 10 Mechanism of Action, H2 2014 96
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 97
Number of Products by Top 10 Route of Administration, H2 2014 100
Number of Products by Stage and Top 10 Route of Administration, H2 2014 101
Number of Products by Top 10 Molecule Type, H2 2014 102
Number of Products by Stage and Top 10 Molecule Type, H2 2014 103

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *